Effects of antipsychotics on the unborn child: What is known and how should this influence prescribing?

Paediatric Drugs

Volumn 2, Issue 2, 2000, Pages 83-90

  Pinkofsky, Harold B ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE;

APGAR SCORE; BIRTH DEFECT; CONGENITAL MALFORMATION; ELECTROCONVULSIVE THERAPY; FETUS; FETUS RISK; HUMAN; PREGNANCY; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; TERATOGENICITY;

EID: 0034108329     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200002020-00001     Document Type: Review

References (76)

1. 1. Strauss GD. Diagnosis and psychiatry: examination of the psychiatric patient. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 6th ed. Baltimore (MD): Williams and Wilkins, 1995: 539
2. 2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
3. 3. Nurnberg HG. An overview of somatic treatment of psychosis during pregnancy and postpartum. Gen Hosp Psychiatry 1989 Sep: 11 (5): 328-38
4. 4. Glaze R, Chapman G, Murray D. Recurrence of psychosis during late pregnancy. Br J Psychiatry 1991 Oct; 159: 567-9
5. 5. McEwen BS, Parsons B. Gonadal steroid action on the brain: neurochemistry and neuropharmacology. Ann Rev Pharmacol Toxicol 1982; 22: 555-98
6. 6. Altshuler LL, Szuba MP. Course of psychiatric disorders in pregnancy. Neurol Clin 1994 Aug; 12 (3): 613-35
7. 7. Carpenter WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990 Jun; 147 (9): 1138-48
8. 8. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987 May; 150: 662-73
9. 9. McNeil TF, Kaij L, Malmquist-Larsson A. Women with nonorganic psychosis: factors associated with pregnancy's effect on mental health during pregnancy. Acta Psychiatr Scand 1984 Sep; 70 (3): 140-8
10. 10. Grunebaum HU, Abernathy VD, Rotman ES, et al. The family planning attitudes, practices, and motivation of mental patients. Am J Psychiatry 1971 Dec; 128 (6): 740-4
11. 11. Wisner KL, Peindl K, Hanusa BH. Symptomatology of affective and psychotic illnesses related to childbearing. J Affect Disord 1994 Feb; 30 (2): 77-87
12. 12. Pozzo EED, Marsh FH. Psychosis and pregnancy: some new ethical and legal dilemmas for the physician. Am J Obstet Gynecol 1987 Feb; 156 (2): 425-7
13. 13. Miller LJ. Sexuality, reproduction and family planning in women with schizophrenia. Schizophr Bull 1997; 23 (4): 623-35
14. 14. Calabrese JR, Gulledge AD. Psychotropics during pregnancy and lactation: a review. Psychosomatics 1985; 26 (5): 413-26
15. 15. Rudolph B, Larson GL, Sweeny S, et al. Hospitalized pregnant psychotic women: characteristics and treatment issues. Hosp Community Psychiatry 1990 Feb 6; 41 (2): 159-63
16. 16. Casiano ME, Hawkins DR. Major mental illness and child bearing: a role for the consultation-liaison psychiatrist in obstetrics. Psychiatric Clin North Am 1987 Mar; 10 (1): 35-51
17. 17. Mortola JF. The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989 Mar; 12 (1): 69-87
18. 18. Janicak PG, Davis JM, Preskorn SH, et al., editors. Principles and practice of psychopharmacotherapy. Baltimore (MD): Williams and Wilkins, 1993: 93-184, 481-4
19. 19. Heinonen OP, Slone D, Shapiro S. Birth defects and drug in pregnancy. Littleton (MA): Publishing Sciences Group, 1977
20. 20. Golbe LI. Parkinson's disease and pregnancy. Neurology 1987 Jul; 37 (7): 1245-9
21. 21. Rosa F. Amantidine pregnancy experience [letter]. Reprod Toxicol 1994; 8: 531
22. 22. Sherer DM, D'Amico ML, Warshal DP, et al. Recurrent mild abruptio placentae occurring immediately after repeated electroconvulsive therapy in pregnancy. Am J Obstet Gynecol 1991 Sep; 165 (3): 652-3
23. 23. Repke JT, Berger NG. Electroconvulsive therapy in pregnancy. Obstet Gjnecol 1984 Mar; 63 (3 Suppl.): 39s-41s
24. 24. Sobel DE. Fetal damage due to ECT, insulin coma, chlorpromazine or reserpine. Arch Gen Psychiatry 1960; 2: 606-11
25. 25. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Commun Psychiatry 1994 May; 45 (5): 444-50
26. 26. Walker R, Swartz CM. Electroconvulsive therapy during high-risk pregnancy. Gen Hosp Psychiatry 1994 Sep; 16 (5): 348-353
27. 27. Green TP, O'Dea RF, Mikin BL. Determinants of drug disposition and effects in fetus. Ann Rev Pharmacol Toxicol 1979; 19: 285-322
28. 28. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: An epidemiologic reassessment. Compr Psychiatry 1984 Jan-Feb; 25 (1): 32-7
29. 29. Guze BH, Guze PA. Psychotropic medication use during pregnancy. West J Med 1989 Sep; 151 (3): 296-8
30. 30. Cohen LS. Psychotropic drug use in pregnancy. Hosp Commun Psychiatry 1989 Jun; 40 (6): 566-7
31. 31. Cohen LS, Heller VL, Rosenbaum JF. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 1989 Win; 30 (1): 25-33
32. 32. Van Waes A, Van De Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1960 Jul-Aug; 9: 224-7
33. 33. Hill RM, Stern L. Drugs in pregnancy: effects on the fetus and newborn. Drugs 1979 Mar; 17 (3): 182-97
34. 34. Milkovich L, Van Den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976; 125: 244-8
35. 35. Slone D, Siskind V, Heinonen O, et al. Antenatal exposure to phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977 Jul; 128 (5): 486-8
36. 36. Rumeau-Rouqette C, Goujard J, Huel G. Possible teratogenic effects of phenothiazine in human beings. Teratology 1977 Feb; 15 (1): 57-64
37. 37. Altshuler LL, Cohen L, Szuba MP, et al. Psychopharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996 May; 153 (5) 592-606
38. 38. Pinkofsky HB, Fitz-Gerald MJ, Reeves RR. Psychotropic treatment during pregnancy [letter]. Am J Psychiatry 1977; 154 (5): 718-9
39. 39. Kopelman AE, McCullar FW, Heggeness L. Limb malformation following maternal use of haloperidol. JAMA 1975 Jan 6; 231 (1): 62-4
40. 40. Dieulangard P, Coignet J, Vical JC. Sur un eas d'ecto phocomelia, peut etre d'origine medicamenteuse. Bull Fed Gynecol Obstet 1966; 18: 85-7
41. 41. Hanson JW, Oakley GP. Haloperidol and limb deformity [letter]. JAMA 1975 Jan 6; 231 (1): 26
42. 42. Ananth J. Congenital malformations with psychopharmacologic agents. Compr Psychiatry 1975 Sep-Oct; 16 (5): 598-600
43. 43. Moriarity AJ, Nance MR. Trifluoperazine and pregnancy [letter]. Can Med Assoc J 1963; 88: 375-6
44. 44. Bracken MB, Holford TR. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 1981; 58: 336-44
45. 45. Sobel DE. Infant mortality and malformations in children of schizophrenic women. Psychiatr Q 1961; 35: 60-4
46. 46. Rieder RO, Rosenthal D, Wender P, et al. The offspring of schizophrenics, fetal and neonatal deaths. Arch Gen Psychiatry 1975 Feb; 32 (2): 200-11
47. 47. Wrede G, Mednick SA, Huttunen MO, et al. Pregnancy and delivery complications in births of an unselected series of Finnish children with schizophrenic mothers. Acta Psychiatr Scand 1980 Oct; 62 (4): 369-81
48. 48. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a metanalysis of case-control studies. Psychol Med 1996 Mar; 26 (2): 279-87
49. 49. Walker E, Emory E. Infants at risk for psychopathology: offspring of schizophrenic parents. Child Dev 1983 Oct; 54 (5): 1269-85
50. 50. Nurnberg HG, Prudic J. Guidelines for treatment of psychosis during pregnancy. Hosp Commun Psychiatry 1984 Jan; 35 (1): 67-71
51. 51. Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 1966 Oct; 69 (4): 589-95
52. 52. O'Connor M, Johnson GH, James DI. Intrauterine effect of phenothiazines. Med J Aust 1981 Apr; 1 (8): 416-7
53. 53. Cleary MF. Fluphenazine decanoate during pregnancy. Am J Psychiatry 1977 Jul; 134 (7): 815-6
54. 54. Levy W, Wisniewski K. Chlorpromazine causing extrapyramidal dysfunction. N Y State J Med 1974 Apr; 74 (4): 684-5
55. 55. Tamer A, McKey R, Arias D, et al. Phenothiazine-induced extrapyramidal dysfunction in the neonate. J Pediatr 1969 Sep; 75 (3): 479-80
56. 56. Auerbach JG, Hans SL, Marcus J, et al. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992; 14 (6): 399-406
57. 57. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980 Aug; 97 (2): 308-10
58. 58. Scokel P, Jones WN. Infant jaundice after phenothiazines. Obstet Gynecol 1962; 20; 124-7
59. 59. Kris E. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res Clin Exp 1965; 7: 785-9
60. 60. Ayd FJ. Children born to mothers treated with chlorpromazine during pregnancy. Clin Med 1964; 71: 1748-63
61. 61. Clarke CV, Gorman D, Vernadakis A. Effects of prenatal administration of psychotropic drugs on behavior of developing rats. Dev Psychobiol 1970; 3 (4): 225-35
62. 62. Spear LP, Shalaby IA, Brach J. Chronic administration of haloperidol during development: behavioral and psychopharmacological effects. Psychopharmacology (Berl) 1980; 70 (1): 47-58
63. 63. Robertson RT, Majka JA, Peter CP, et al. Effects of prenatal exposure to chlorpromazine on postnatal development and behavior of rats. Toxicol Appl Pharmacol 1980 May; 52 (3): 541-9
64. 64. Cunningham FG, MacDonald PC, Gant NF, et al., editors. Williams obstetrics. 19th ed. Norwalk (CT): Appleton and Lange, 1993: 225-30
65. 65. Baldessarini RG. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PG, et al., editors. Goodman and Gillman's the pharmacologic basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 399-430
66. 66. Gelenberg AJ. Psychosis. In: Gelenberg AJ, Bassuk EL, Schoonover SC, editors. The practitioner's guide to psychoactive drugs. 3rd ed. New York: Plenum Press, 1991: 125-78
67. 67. Pinkofsky HB. Psychosis during pregnancy: treatment considerations. Ann Clin Psychiatry 1997 Sep; 9 (3): 175-9
68. 68. Waldman MD, Satterman AZ. Pregnancy and clozapine. Am J Psychiatry 1993 Jan; 150 (1): 168-9
69. 69. Barnas C, Bergnat A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk [letter]. Am J Psychiatry 1994 Jun; 151 (6): 944
70. 70. Jann MW. Clozapine. Pharmacotherapy 1991; 11 (3): 179-95
71. 71. Dickson RA, Dawson DT. Olanzapine and pregnancy. Can J Psychiatry 1998 Mar; 43: 196-7
72. 72. Kuller JA, Katz VL, McMahon ML, et al. Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Obstet Gynecol 1996 May; 87 (5 Pt 1): 789-94
73. 73. Boobis AR, Lewis P. Drugs in pregnancy. Altered pharmacokinetics. Br J Hosp Med 1982 Dec; 28 (6): 566-73
74. 74. Goldberg HL, Nissim R. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry 1994; 24 (2): 129-49
75. 75. Viguera AC, Baldassarini RC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995 Mar; 52 (3): 189-92
76. 76. Decker S, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 1986 Feb; 73 (2): 181-5